Dr Jennifer Munkley
- Email: firstname.lastname@example.org
- Telephone: +44 (0)191 241 8685
- Fax: +44 (0)191 241 8666
- Personal Website: https://twitter.com/munkleylab
- Address: Institute of Genetic Medicine
International Centre for Life
Newcastle upon Tyne
My research aims to exploit an important yet understudied group of sugar molecules (known as glycans) to improve the diagnosis and treatment of cancer. Glycans are found on the cell surface of and secreted by cancer cells and change dramatically in all types of cancer.
Our research into glycosylation has led us to propose that aberrant glycosylation is a general hallmark of all cancers. Glycans are involved in all stages of cancer progression and play key roles in tumour development, growth and invasion. However, the molecular details underlying these changes are poorly understood, and of the four fundamental building blocks of life (proteins, glycans, lipids and nucleic acids) glycans have been the least studied.
In recent work we showed that in prostate cancer the system for making glycans and adding them to the cell (called glycosylation) is turned on by the signals that cause cancers to grow in men and turned off by the therapies which cause tumours to shrink. We also showed that these glycan producing enzymes are upregulated in prostate tumours and are essential for prostate cancer cell survival.
We are now investigating how these glycans influence prostate cancer cell behaviour, testing if they can be targeted by new treatments, and seeing if we can detect them as part of a new blood test to improve diagnosis.
Work in our group is funded by Prostate Cancer UK.
Area of expertise
- Glycosylation in cancer
Google scholar: Click here.
- Munkley J. Glycosylation is a global target for androgen control in prostate cancer cells. Endocrine Related Cancer 2017, 24, R49-R64.
- Munkley J, Livermore K, Rajan P, Elliott DJ. RNA splicing and splicing regulator changes in prostate cancer pathology. Human Genetics 2017, 136(9), 1143-1154.
- Munkley J, McClurg UL, Livermore KE, Ehrmann I, Knight B, McCullagh P, McGrath J, Crundwell M, Harries LW, Leung HY, Mills IG, Robson CN, Rajan P, Elliott DJ. The cancer-associated cell migration protein TSPAN1 is under control of androgens and its upregulation increases prostate cancer cell migration. Scientific Reports 2017, 7(1), 5249.
- Livermore KE, Munkley J, Elliott DJ. Androgen receptor in prostate cancer. AIMS Molecular Science 2016, 3(2), 280-299.
- Munkley J, Vodak D, Livermore KE, James K, Wilson BT, Knight B, Mccullagh P, Mcgrath J, Crundwell M, Harries LW, Leung HY, Robson CN, Mills IG, Rajan P, Elliott DJ. Glycosylation is an Androgen-Regulated Process Essential for Prostate Cancer Cell Viability. eBioMedicine 2016, 8, 103–116.
- Munkley J, Elliott DJ. Hallmarks of glycosylation in cancer. Oncotarget 2016, 7, 35478-35489.
- Neganova A, Shmeleva E, Munkley J, Chichagova V, Anyfantis G, Anderson R, Passos AJ, Elliott DJ, Armstrong L, Lako M. JNK/SAPK signalling is essential for efficient reprogramming of human fibroblasts to induced pluripotent stem cells. Stem Cells 2016, 34(5), 1198-1212.
- Munkley J, Elliott DJ. Sugars and cell adhesion: the role of ST6GalNAc1 in prostate cancer progression. Cancer Cell & Microenvironment 2016, 3(1), e1174.
- Munkley J, Mills IG, Elliott DJ. The role of glycans in the development and progression of prostate cancer. Nature Reviews Urology 2016, 13(6), 324-333.
- Munkley J. The Role of Sialyl-Tn in Cancer. International Journal of Molecular Sciences 2016, 17(3), 275.
- Munkley J, Lafferty NP, Kalna G, Robson CN, Leung HY, Rajan P, Elliott DJ. Androgen-regulation of the protein tyrosine phosphatase PTPRR activates ERK1/2 signalling in prostate cancer. BMC Cancer 2015, 15, 9.
- Wilson B, Strong A, O'Kelly S, Munkley J, Stark Z. Metronidazole Toxicity in Cockayne Syndrome: A Case Series. Pediatrics 2015, 136(3), e706-e708.
- Munkley J, Oltean S, Vodák D, Wilson BT, Livermore KE, Zhou Y, Star E, Floros VI, Johannessen B, Knight B, McCullagh P, McGrath J, Crundwell M, Skotheim RI, Robson CN, Leung HY, Harries LW, Rajan P, Mills IG, Elliott DJ. The androgen receptor controls expression of the cancer-associated sTn antigen and cell adhesion through induction of ST6GalNAc1 in prostate cancer. Oncotarget 2015, 6(33), 34358-34374.
- Munkley J, Livermore KE, McClurg UL, Kalna G, Knight B, McCullagh P, McGrath J, Crundwell M, Leung HY, Robson CN, Harries LW, Rajan P, Elliott DJ. The PI3K regulatory subunit gene PIK3R1 is under direct control of androgens and repressed in prostate cancer cells. Oncoscience 2015, 2(9).
- Boczonadi V, Muller JS, Pyle A, Munkley J, Dor T, Quartararo J, Ferrero I, Karcagi V, Giunta M, Polvikoski T, Birchall D, Princzinger A, Cinnamon Y, Lutzkendorf S, Piko H, Reza M, Florez L, Santibanez-Koref M, Griffin H, Schuelke M, Elpeleg O, Kalaydjieva L, Lochmuller H, Elliott DJ, Chinnery PF, Edvardson S, Horvath R. EXOSC8 mutations alter mRNA metabolism and cause hypomyelination with spinal muscular atrophy and cerebellar hypoplasia. Nature Communications 2014, 5, 4287.
- Munkley J, Rajan P, Lafferty NP, Dalgliesh C, Jackson RM, Robson CN, Leung HY, Elliott DJ. A novel androgen-regulated isoform of the TSC2 tumour suppressor gene increases cell proliferation. OncoTarget 2014, 5(1), 131-139.
- Munkley J, Copeland NA, Moignard V, Knight JR, Greaves E, Ramsbottom SA, Pownall ME, Southgate J, Ainscough JF, Coverley D. Cyclin E is recruited to the nuclear matrix during differentiation, but is not recruited in cancer cells. Nucleic Acids Research 2011, 39(7), 2671-7.